In a 1-year cohort study, Koppelman et al. found 15% of IBD patients in remission relapsed (C-reactive protein (CRP) ≥ 5 mg/L or FC ≥ 150 μg/g), and 40% of those with active disease achieved remission, but Nova 4 UPF intake did not differ between remission and active patients or over time [25]. This evidence concerns the gene CRP and inflammatory bowel disease.